

# SEIZE THE DATA: DATSCAN™ IOFLUPANE I-123


## WITH DaTQUANT™ ANALYTICS

DaTQUANT™ may assist in the detection of loss of functional dopaminergic neuron terminals in the striatum, which is correlated with Parkinson's disease

Quantification capabilities are automated, reproducible and accurate, assisting physicians in the proper diagnosis and care of their patients with Parkinsonian symptoms

### SERVING AS A VALUABLE DIAGNOSTIC ADJUNCT

- The first diagnostic imaging agent to help physicians evaluate neurodegenerative movement disorders, such as idiopathic Parkinson's disease (PD).
- DaTQUANT™ provides fast Ioflupane I-123 SPECT image quantitative analysis including:
  - ✓ Computation of uptake values in the striatum.
  - ✓ Striatal binding ratios
  - ✓ Putamen/caudate ratios
  - ✓ Left/right asymmetry
- Consistent, repeatable and accurate analysis.
- SPECT images with DaTscan™ may provide a reliable assessment of striatal DaT receptor distribution.



DaTscan™ studies with DaTQUANT™ analysis is performed exclusively at the DIS Women's & Advanced Imaging Center in Metairie

Order CPT Code 78607 and check the [DaTscan](#) nuclear medicine option on your DIS referral order

Appointment Scheduling (south)

Phone: 504-883-5999

Fax: 504-883-5364

Appointment Scheduling (north)

Phone: 985-641-2390

Fax: 985-641-2854

Visit [www.disnola.com/referring-providers](http://www.disnola.com/referring-providers) for more information



Doctor TruSted. Patient Preferred.

# DATSCAN™ IOFLUPANE I-123 INJECTION

## PATIENT PREPARATION

Drugs that bind to the dopamine transporter with high affinity may interfere with the DaTscan image. Whether discontinuation of these drugs prior to DaTscan administration may minimize the interference with a DaTscan image is unknown. The impact of dopamine agonists and antagonists upon DaTscan imaging results has not been established. The benefits and risks of stopping a medication regimen prior to DaTscan administration is a patient specific medical consideration. **The decision to withhold or stop any medication should be determined by the patient's physician(s).**

Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. *J Neurol Neurosurg Psychiatry*. 2010;81:5-12.

Relevant drug interaction with dopamine transporter single photon emission tomography (DAT-SPECT). This is not a comprehensive list of medications.

Minor <sup>1</sup> effect on DAT-SPECT	To be stopped prior to DAT-SPECT	Significant <sup>2</sup> effect on DAT-SPECT	To be stopped prior to DAT-SPECT
Citalopram	8 days	Cocaine <sup>3</sup>	2 days
Fluoxetine	45 days	Amphetamine	7 days
Paroxetine	5 days	Methylamphetamine	3 days
Venlafaxine	3 days	Methylphenidate	2 days
Duloxetine	3 days	Dexamphetamine	7 days
Escitalopram	8 days	Mazindol	3 days
Fluvoxamine	5 days	Phentermine	14 days
Sertraline	6 days	Modafinil	3 days
Imipramine	5 days	Bupropion or Amfebutamone	8 days
Clomipramine	21 days	Benztropine	5 days
Pimozide <sup>3</sup>	28 days		
Ziprasidone	2 days		
Memantine	5 days		
Amantadine	6 days		
Budipine <sup>3</sup>	6 days		
Ephedrine, epinephrine	6-10 hours		
Phenylephrine			
Pseudoephedrine			
Xylometazoline <sup>3</sup>			

<sup>1</sup>May have a small effect on uptake (at most 15%). This is acceptable for routine DAT-SPECT but not for research.

<sup>2</sup>All of these drugs are likely to alter (usually decrease) radioligand uptake by at least 20% and often substantially more, and therefore have to be stopped prior to DAT-SPECT.

<sup>3</sup>Not FDA-approved

**Appointment Scheduling (south)**

Phone: 504-883-5999

Fax: 504-883-5364

**Appointment Scheduling (north)**

Phone: 985-641-2390

Fax: 985-641-2854

**Visit [www.disnola.com/referring-providers](http://www.disnola.com/referring-providers) for more information**



Doctor Trusted. Patient Preferred.